JPWO2021142247A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021142247A5 JPWO2021142247A5 JP2022541815A JP2022541815A JPWO2021142247A5 JP WO2021142247 A5 JPWO2021142247 A5 JP WO2021142247A5 JP 2022541815 A JP2022541815 A JP 2022541815A JP 2022541815 A JP2022541815 A JP 2022541815A JP WO2021142247 A5 JPWO2021142247 A5 JP WO2021142247A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- cancer
- compound
- alkyl
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062959502P | 2020-01-10 | 2020-01-10 | |
| US62/959,502 | 2020-01-10 | ||
| PCT/US2021/012683 WO2021142247A1 (en) | 2020-01-10 | 2021-01-08 | Smarca2-vhl degraders |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2023510746A JP2023510746A (ja) | 2023-03-15 |
| JPWO2021142247A5 true JPWO2021142247A5 (https=) | 2024-01-16 |
| JP2023510746A5 JP2023510746A5 (https=) | 2024-01-16 |
| JP7706456B2 JP7706456B2 (ja) | 2025-07-11 |
Family
ID=74495106
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022541815A Active JP7706456B2 (ja) | 2020-01-10 | 2021-01-08 | Ｓｍａｒｃａ２－ｖｈｌ分解剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230091042A1 (https=) |
| EP (1) | EP4087658A1 (https=) |
| JP (1) | JP7706456B2 (https=) |
| AU (1) | AU2021205326A1 (https=) |
| CA (1) | CA3167166A1 (https=) |
| MX (1) | MX2022008487A (https=) |
| WO (1) | WO2021142247A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019140380A1 (en) | 2018-01-12 | 2019-07-18 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| WO2020010227A1 (en) | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| WO2020251972A1 (en) | 2019-06-10 | 2020-12-17 | Kymera Therapeutics, Inc. | Smarca degraders and uses thereof |
| WO2021133917A1 (en) | 2019-12-23 | 2021-07-01 | Kymera Therapeutics, Inc. | Smarca inhibitors and uses thereof |
| BR112022012410A2 (pt) | 2019-12-23 | 2022-08-30 | Kymera Therapeutics Inc | Degradadores smarca e usos dos mesmos |
| WO2022029617A1 (en) * | 2020-08-04 | 2022-02-10 | Aurigene Discovery Technologies Limited | 6-substituted pyridazine compounds as smarca2 and/or smarca4 degraders |
| EP4259144A4 (en) * | 2020-12-09 | 2025-08-20 | Kymera Therapeutics Inc | SMARCA DEGRADING AGENTS AND THEIR USES |
| US11993599B2 (en) | 2021-08-09 | 2024-05-28 | Genentech, Inc. | Therapeutic compounds |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10519152B2 (en) * | 2017-12-21 | 2019-12-31 | Astrazeneca Ab | Compounds and their use in treating cancer |
| US20190300521A1 (en) * | 2018-04-01 | 2019-10-03 | Arvinas Operations, Inc. | Brm targeting compounds and associated methods of use |
| US12371426B2 (en) * | 2018-04-26 | 2025-07-29 | Aurigene Discovery Technologies Limited | Pyridazine derivatives as SMARCA2/4 degraders |
| WO2019213005A1 (en) * | 2018-04-30 | 2019-11-07 | Dana-Farber Cancer Institute, Inc. | Small molecule degraders of polybromo-1 (pbrm1) |
-
2021
- 2021-01-08 AU AU2021205326A patent/AU2021205326A1/en active Pending
- 2021-01-08 EP EP21702829.9A patent/EP4087658A1/en active Pending
- 2021-01-08 CA CA3167166A patent/CA3167166A1/en active Pending
- 2021-01-08 US US17/788,272 patent/US20230091042A1/en active Pending
- 2021-01-08 WO PCT/US2021/012683 patent/WO2021142247A1/en not_active Ceased
- 2021-01-08 JP JP2022541815A patent/JP7706456B2/ja active Active
- 2021-01-08 MX MX2022008487A patent/MX2022008487A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020508310A5 (https=) | ||
| JPWO2019195124A5 (https=) | ||
| CN111989332A (zh) | 作为cdk抑制剂的大环化合物、其制备方法及其在医药上的应用 | |
| JP2010505930A5 (https=) | ||
| JP2009507909A5 (https=) | ||
| JP2020534264A5 (https=) | ||
| RU2011130511A (ru) | Аденовирусные векторы и способы их применения, связанные с ними | |
| JP2007511504A5 (https=) | ||
| JP2006526590A5 (https=) | ||
| JP2011057693A5 (https=) | ||
| JPWO2021142247A5 (https=) | ||
| JPWO2020123827A5 (https=) | ||
| RU2021130306A (ru) | Композиции il-12, нацеленные на edb | |
| CA2550350A1 (en) | 2-(hetero)aryl-substituted tetrahydroquinoline derivatives | |
| JP2020534300A5 (https=) | ||
| CN116113416A (zh) | 四环类衍生物、其制备方法和其医药上的用途 | |
| JPH09165336A5 (https=) | ||
| JP7229482B2 (ja) | 新規アミド系化合物、並びにそれを用いたＰｉｎ１阻害剤、炎症性疾患の治療剤及び癌の治療剤 | |
| JP2013544794A5 (https=) | ||
| JP2016540826A5 (https=) | ||
| JPWO2019154986A5 (https=) | ||
| JP2018528949A5 (https=) | ||
| JPWO2020051356A5 (https=) | ||
| CA3167918A1 (en) | Compositions and methods for modulating cancer | |
| Teicher et al. | Signal transduction inhibitors as modifiers of radiation therapy in human prostate carcinoma xenografts |